COVID-19: Discovery Spurs Clinical Trial of Antidepressant (2 of 2) (IMAGE)

University of Virginia Health System

COVID-19: Discovery Spurs Clinical Trial of Antidepressant (2 of 2)

Caption

Dorian A Rosen, Ph.D., (left) and Alban Gaultier, Ph.D., found last year that fluvoxamine can reduce the production of immune cells known as cytokines. Excess production of cytokines can lead to potentially deadly "cytokine storms" in patients with severe COVID-19.

Credit

Dan Addison | UVA Communications

Usage Restrictions

May be used to accompany news coverage of the COVID trial. All other uses require express written permission from UVA Health.

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.